Search Results
Jun 30, 2026, 09:00 ET A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs
patient dosed in May 2026.Other publicly traded names across NK-cell, immune-engager, and AI-discovery approaches include Nkarta (NASDAQ: NKTX), Fate Therapeutics (NASDAQ: FATE), Compass Therapeutics (NASDAQ: CMPX), and Recursion (NASDAQ: RXRX), each distinct, and none a proxy for GT Biopharma.Putting
More news about: USA News Group
May 29, 2026, 09:00 ET The $13 Million Company Teaching the Immune System to Hunt Cancer
fund an NK/cell-therapy platform it believes in — a striking counterpoint to GTBP's microcap valuation.Nkarta (NASDAQ: NKTX) is the engineered-NK-cell specialist, advancing its platform into autoimmune disease and backed by a market capitalization and cash position orders
More news about: USA News Group
May 19, 2026, 09:00 ET Three TriKE Candidates In Clinic As NK Cell Engager Field Reorganizes
Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ: GTBP), Fate Therapeutics, Inc. (NASDAQ: FATE), Nkarta, Inc. (NASDAQ: NKTX), ImmunityBio, Inc. (NASDAQ: IBRX), INmune Bio, Inc. (NASDAQ: INMB)SAN FRANCISCO, May
More news about: Equity Insider